Shares of Baxter International (BAX) Rally 0.26%

On a relative basis, the stock has outperformed the S&P 500 by 0.84% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.26% in the last 1 week, and is up 5.24% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.23% and the 50-Day Moving Average is 4.71%.

Baxter International (NYSE:BAX): The stock opened at $47.08 on Friday but the bulls could not build on the opening and the stock topped out at $47.20 for the day. The stock traded down to $46.56 during the day, due to lack of any buying support eventually closed down at $46.77 with a loss of -0.38% for the day. The stock had closed at $46.95 on the previous day. The total traded volume was 2,961,651 shares.


The company Insiders own 1.08% of Baxter International shares according to the proxy statements. Institutional Investors own 85.28% of Baxter International shares. During last six month period, the net percent change held by insiders has seen a change of -23.18%. In a related news, Almeida Jose E, CEO of Baxter International Inc had purchased 11,691 shares on May 23, 2016 in a transaction. The price per share was $42.75 and the total amount of the disclosed transaction was $499,790.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.